BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide. Genetic polymorphism has been reported as a predictive factor related to a higher risk for HCC. Because the stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, have been reported to play important roles in tumor cell proliferation, angiogenesis, and metastasis of HCC, the aim of this study was to estimate the relationship between SDF-1 and CXCR4 gene variants to HCC risk and clinicopathological status. METHODS: Polymerase chain reaction-restriction fragment length polymorphism was used to measure SDF-1 (rs1801157) and CXCR4 (rs2228014) gene polymorphisms in 311 healthy controls and 102 patients with HCC. RESULTS: Compared to controls, individuals with at least one A allele had a higher risk of 1.57-fold (95% CI: 1.00-2.47) to induce HCC and had a risk of 2.81-fold (95% CI: 1.04-7.58) to develop a status of stage III or stage IV disease, after being adjusted for other confounders. However, there was no significant association between CXCR4 gene polymorphism and either HCC risk or pathological status. Additionally, both gene polymorphisms were not associated with the serum expression of liver-related clinical pathological markers. CONCLUSIONS: SDF-1-3'A gene polymorphism could be considered as a factor related to an increased susceptibility to the risk and pathological development of HCC.
BACKGROUND:Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide. Genetic polymorphism has been reported as a predictive factor related to a higher risk for HCC. Because the stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, have been reported to play important roles in tumor cell proliferation, angiogenesis, and metastasis of HCC, the aim of this study was to estimate the relationship between SDF-1 and CXCR4 gene variants to HCC risk and clinicopathological status. METHODS: Polymerase chain reaction-restriction fragment length polymorphism was used to measure SDF-1 (rs1801157) and CXCR4 (rs2228014) gene polymorphisms in 311 healthy controls and 102 patients with HCC. RESULTS: Compared to controls, individuals with at least one A allele had a higher risk of 1.57-fold (95% CI: 1.00-2.47) to induce HCC and had a risk of 2.81-fold (95% CI: 1.04-7.58) to develop a status of stage III or stage IV disease, after being adjusted for other confounders. However, there was no significant association between CXCR4 gene polymorphism and either HCC risk or pathological status. Additionally, both gene polymorphisms were not associated with the serum expression of liver-related clinical pathological markers. CONCLUSIONS:SDF-1-3'A gene polymorphism could be considered as a factor related to an increased susceptibility to the risk and pathological development of HCC.
Authors: Bhawna Dubey; Maria D Jackson; Charnita Zeigler-Johnson; Karthik Devarajan; Rafael E Flores-Obando; Norma McFarlane-Anderson; Marshall K Tulloch-Reid; William Aiken; Kevin Kimbro; Dominique Z Jones; LaCreis R Kidd; Camille Ragin Journal: Gene Date: 2017-09-10 Impact factor: 3.688
Authors: Paige M Bracci; Christine F Skibola; Lucia Conde; Eran Halperin; Tracy Lightfoot; Alex Smith; Randi A Paynter; Danica R Skibola; Luz Agana; Eve Roman; Eleanor Kane; John K Wiencke Journal: Leuk Lymphoma Date: 2010-03
Authors: Lacreis R Kidd; Dominique Z Jones; Erica N Rogers; Nayla C Kidd; Sydney Beache; James E Rudd; Camille Ragin; Maria Jackson; Norma McFarlane-Anderson; Marshall Tulloch-Reid; Seian Morrison; Guy N Brock; Shirish S Barve; Kevin S Kimbro Journal: Hered Cancer Clin Pract Date: 2012-11-20 Impact factor: 2.857